Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06391008
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-30
First Post:
2024-04-25
Brief Title:
Immunosensitized Radiotherapy Combined With Evoximab AK112 and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer
Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Organization:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study Overview
Official Title:
Immunosensitized Radiotherapy Combined With Evoximab AK112 and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer a Single Arm Open Label Phase II Clinical Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open label prospective single center Phase II clinical study Intended to evaluate the main pathological response rate MPR and safety of stereotactic immunosensitized radiotherapy combined with Evoximab PD-1VEGF-A bispecific antibody and chemotherapy neoadjuvant therapy for stage II-III NSCLC Simultaneously observe and evaluate the complete pathological response rate pCR R0 resection rate and event free survival EFS of stage II-III NSCLC treated with stereotactic radiotherapy combined with Evoximab PD-1VEGF-A bispecific antibody and chemotherapy Exploratory analysis based on serumtumor molecular biological markers as well as the optimal response time and mechanism for combined response
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None